Abstract
Abstract
Purpose
To develop a radiomics model for the characterization of renal nodules on CT.
Methods
Patients who underwent surgical resection of renal nodules, with preoperative CT (LightSpeed VCT, GE) with contrast agent (Iopamidol 370; 1.5 ml/kg) and availability of a histopathological report, were retrospectively included. Renal lesions were segmented by two radiologists in consensus, in the arterial phase on the axial section with greater diameter. The radiomics analysis was performed with validated software (PyRadiomics on Syngo.via Frontier, Siemens) by applying normalization, resampling (1,1,1), setting bin width (15), and applying padding (2). The extracted features were used for training and testing machine learning models (random forest and support vector machine (end point: clear cell carcinoma, ccRCC).
Results
45 patients were included (mean age 56 years; 34/45 ccRCC). SVM e RF models obtained an AUC of 0.84 and accuracy of 0.87 and 0.80, respectively, in the testing phase.
Conclusion
Radiomics analysis is feasible and effective in the characterization of renal lesions on CT.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Caliò A, Marletta S, Brunelli M, Martignoni G (2023) WHO 2022 classification of kidney tumors: What is relevant? An update and future novelties for the pathologist. Pathologica 115:23–31. https://doi.org/10.32074/1591-951X-814
2. Ferlay J EMLFLMCMMLPMZASIBF (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer Available from: https://gco.iarc.who.int/today
3. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
4. Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149:778–789. https://doi.org/10.1002/ijc.33588
5. Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12–49. https://doi.org/10.3322/caac.21820